AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19425829 — intervention group
Group type: COMPARATOR
Intervention: 4.0-microm droplets
Number of subjects: 15
Study 19425829 — intervention group
Group type: COMPARATOR
Intervention: 5.0-microm droplets
Number of subjects: 15
Study 17061636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose in 0.9% normal saline
Number of subjects: 50
Study 17061636 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 50
Study 17061636 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 50
Study 15069909 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based continuing medical education (CME)
Number of subjects: 16
Study 15069909 — intervention group
Group type: COMPARATOR
Intervention: Traditional formats of CME
Number of subjects: 16
Study 11746343 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects model
Number of subjects: 84
Study 11746343 — intervention group
Group type: COMPARATOR
Intervention: Fixed effects model
Number of subjects: 84
Study 9250453 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and system interventions
Number of subjects: 352
Study 8100184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3752418 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of birch pollen preparation (n = 11)
Number of subjects: 24
Study 3752418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 24
Study 31705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus verbal information
Number of subjects: 113
Study 31705869 — intervention group
Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 113
Study 29742567 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 76
Study 29742567 — intervention group
Group type: COMPARATOR
Intervention: Traditional bur
Number of subjects: 76
Study 27916815 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of Ca-P (n = 30)
Number of subjects: 70
Study 27916815 — intervention group
Group type: COMPARATOR
Intervention: Low intake of Ca-P (n = 40)
Number of subjects: 70
Study 27916815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low gestational age and male gender
Number of subjects: 70
Study 27916815 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 70
Study 24084157 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated albumin excretion rate (eAER)
Number of subjects: 1693
Study 24084157 — intervention group
Group type: COMPARATOR
Intervention: Urine albumin-creatinine ratio (ACR)
Number of subjects: 1693
Study 21871811 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace
Number of subjects: 58
Study 21871811 — intervention group
Group type: COMPARATOR
Intervention: Unbraced condition
Number of subjects: 58
Study 21871811 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced condition
Number of subjects: 58
Study 18972097 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2627
Study 18972097 — intervention group
Group type: COMPARATOR
Intervention: Non-HDLC:HDLC ratio
Number of subjects: 2627
Study 17136309 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 200
Study 17136309 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 200
Study 15584360 — intervention group
Group type: EXPERIMENTAL
Intervention: Melitrast-270
Number of subjects: 100
Study 15584360 — intervention group
Group type: EXPERIMENTAL
Intervention: Melitrast-300
Number of subjects: 100
Study 15584360 — intervention group
Group type: EXPERIMENTAL
Intervention: Melitrast-270 and Melitrast-300
Number of subjects: 100
Study 11222362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and prolonged asparaginase intensification (30 weeks)
Number of subjects: 377
Study 11222362 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase treatment duration (at least 26 weeks)
Number of subjects: 377
Study 11222362 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 377
Study 11222362 — intervention group
Group type: COMPARATOR
Intervention: Risk group (standard risk vs high risk)
Number of subjects: 377
Study 9555799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UVA1 phototherapy (UVA1R; 10 days, 130 J/cm2/day; n = 20)
Number of subjects: 53
Study 9555799 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluocortolone (10 days, 1 x daily; n = 17)
Number of subjects: 53
Study 9555799 — intervention group
Group type: COMPARATOR
Intervention: UVA-UVB therapy (10 days, 1 x daily, minimal erythema dose-dependent; n = 16)
Number of subjects: 53
Study 7809356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypochondriasis
Number of subjects: 100
Study 7809356 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 100
Study 2903322 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TM), 30 mg daily for 2 years
Number of subjects: 433
Study 2903322 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus Tamoxifen (TM)
Number of subjects: 433
Study 2903322 — intervention group
Group type: COMPARATOR
Intervention: CMF alone
Number of subjects: 433
Study 6121545 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride administration in neuroleptic-treated schizophrenics
Number of subjects: 58
Study 6121545 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride administration in total schizophrenic population
Number of subjects: 58
Study 6121545 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride administration in manic patients
Number of subjects: 58
Study 31965834 — intervention group
Group type: EXPERIMENTAL
Intervention: UB0316 (probiotic)
Number of subjects: 90
Study 31965834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28096659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days)
Number of subjects: 16
Study 28096659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28096659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 16
Study 25304864 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 129
Study 25304864 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg
Number of subjects: 129
Study 25304864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 24700260 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange ice lollies
Number of subjects: 69
Study 24700260 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-citrus ice lollies
Number of subjects: 69
Study 24700260 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (deep breaths)
Number of subjects: 69
Study 22692271 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste twice daily for three minutes and AmF/SnF2 mouthrinse for 30 seconds
Number of subjects: 40
Study 22692271 — intervention group
Group type: COMPARATOR
Intervention: AmF/SnF2 toothpaste twice daily for three minutes
Number of subjects: 40
Study 22692271 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste with mouthrinse
Number of subjects: 40
Study 22692271 — intervention group
Group type: COMPARATOR
Intervention: AmF/SnF2 toothpaste without mouthrinse
Number of subjects: 40
Study 19631850 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical endodontic treatment
Number of subjects: 0
Study 17215184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention villages (traditional food intervention)
Number of subjects: 0
Study 17215184 — intervention group
Group type: COMPARATOR
Intervention: Control villages (no intervention)
Number of subjects: 0
Study 17215184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers from intervention villages
Number of subjects: 0
Study 15224028 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1); n = 18)
Number of subjects: 36
Study 15224028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study 15224028 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 36
Study 15224028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15224028 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine and placebo
Number of subjects: 36
Study 12169328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 12169328 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic group
Number of subjects: 21
Study 9848039 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol preservation (70% and 85%)
Number of subjects: 0
Study 9848039 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol preservation
Number of subjects: 0
Study 9848039 — intervention group
Group type: COMPARATOR
Intervention: Cryopreservation (10% dimethyl sulfoxide)
Number of subjects: 0
Study 8026205 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous postural therapy on an oscillating bed
Number of subjects: 19
Study 8026205 — intervention group
Group type: COMPARATOR
Intervention: Conventional frequency of manual postural changes (Control)
Number of subjects: 19
Study 2690332 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 30 mg once daily
Number of subjects: 176
Study 2690332 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 200 mg t.d.s. and 400 mg at bedtime
Number of subjects: 176
Study 1015496 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide intravenously
Number of subjects: 49
Study 1015496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium metabisulfite) intravenously
Number of subjects: 49
Study 31031045 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (pulsed and conventional) on the saphenous nerve and genicular nerves
Number of subjects: 28
Study 31031045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLCB)
Number of subjects: 28
Study 28823684 — intervention group
Group type: COMPARATOR
Intervention: Light exercise
Number of subjects: 620
Study 28823684 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 620
Study 28823684 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 620
Study 28823684 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 620
Study 25960826 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 15
Study 25960826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VitC) supplementation
Number of subjects: 15
Study 25960826 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and VitC supplementation together
Number of subjects: 15
Study 25960826 — intervention group
Group type: COMPARATOR
Intervention: PMA activation
Number of subjects: 15
Study 23213004 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept and methotrexate (ETN + MTX)
Number of subjects: 62
Study 23213004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (various DMARDs)
Number of subjects: 62
Study 21768764 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening for MRSA using polymerase chain reaction (PCR) on samples collected from all adult patients upon admission.
Number of subjects: 15049
Study 21768764 — intervention group
Group type: COMPARATOR
Intervention: Targeted screening for MRSA conducted during a 9-month baseline period.
Number of subjects: 15049
Study 19500083 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Number of subjects: 338
Study 19500083 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 338
Study 17483854 — intervention group
Group type: EXPERIMENTAL
Intervention: Care recipients often visit physicians or have medical examinations
Number of subjects: 0
Study 17483854 — intervention group
Group type: EXPERIMENTAL
Intervention: Care recipients take medicines that affect the central nervous system or stomach
Number of subjects: 0
Study 17483854 — intervention group
Group type: EXPERIMENTAL
Intervention: Care recipients seldom visit nurses
Number of subjects: 0
Study 17483854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers have chronic disease or cancer
Number of subjects: 0
Study 17483854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver experience distress, feel lonely, or have an unsatisfactory relationship with patients
Number of subjects: 0
Study 17483854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's smoking and drinking
Number of subjects: 0
Study 15454833 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC (Avemar) with cytotoxic drugs
Number of subjects: 22
Study 15454833 — intervention group
Group type: COMPARATOR
Intervention: Control (cytotoxic drugs without MSC)
Number of subjects: 22
Study 11406737 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for 5 days
Number of subjects: 10
Study 11406737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9803198 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for cough or bronchitis
Number of subjects: 0
Study 9803198 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric treatment for pharyngitis
Number of subjects: 0
Study 9803198 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for common cold
Number of subjects: 0
Study 7816388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder sludge
Number of subjects: 51
Study 7816388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstones
Number of subjects: 51
Study 7816388 — intervention group
Group type: COMPARATOR
Intervention: Normal gallbladders
Number of subjects: 51
Study 7816388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder sludge or stones
Number of subjects: 51
Study 3049216 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon therapy (4-month duration)
Number of subjects: 45
Study 3049216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 3049216 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon therapy
Number of subjects: 45
Study 31486917 — intervention group
Group type: EXPERIMENTAL
Intervention: Total keratometry (TK)
Number of subjects: 60
Study 31486917 — intervention group
Group type: COMPARATOR
Intervention: Conventional keratometry (K)
Number of subjects: 60
Study 28482869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg per day in 100 ml 0.9% sodium chloride)
Number of subjects: 112
Study 28482869 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous fumarate (200 mg per day)
Number of subjects: 112
Study 25501671 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 150 mg/day
Number of subjects: 42
Study 25501671 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 5 mg/day
Number of subjects: 42
Study 25501671 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50 mg/day
Number of subjects: 42
Study 23296713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLLT (808 nm wavelength, 100 mW, energy 7 J)
Number of subjects: 24
Study 23296713 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 24
Study 21701181 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy intervention
Number of subjects: 74
Study 21701181 — intervention group
Group type: COMPARATOR
Intervention: Dropouts
Number of subjects: 74
Study 21701181 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapist and supervisor perspectives
Number of subjects: 74
Study 18253828 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis (GMCAP)
Number of subjects: 13
Study 18253828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adacolumn apheresis
Number of subjects: 13
Study 16490980 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine (Betadine) with compression bandages
Number of subjects: 63
Study 16490980 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine (Betadine) without compression bandages
Number of subjects: 63
Study 16490980 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (amoxicillin)
Number of subjects: 63
Study 16490980 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine (Betadine)
Number of subjects: 63
Study 12601503 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 0
Study 12601503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12601503 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 0
Study 12601503 — intervention group
Group type: COMPARATOR
Intervention: No caffeine
Number of subjects: 0
Study 10834429 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg)
Number of subjects: 8
Study 9533322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-plus-debridement
Number of subjects: 0
Study 9533322 — intervention group
Group type: COMPARATOR
Intervention: Placebo-plus-debridement
Number of subjects: 0
Study 8450096 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0
Study 8450096 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion
Number of subjects: 0
Study 8450096 — intervention group
Group type: EXPERIMENTAL
Intervention: No shows
Number of subjects: 0
Study 8450096 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 0
Study 3512352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa (slow-release 5'-aminosalicylic acid)
Number of subjects: 12
Study 3512352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29277312 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal transversus abdominis plane block
Number of subjects: 76
Study 29277312 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative analgesia
Number of subjects: 76
Study 27811457 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐rich drink group (Group C, n = 30)
Number of subjects: 90
Study 27811457 — intervention group
Group type: COMPARATOR
Intervention: Preoperative fasting from midnight (Group F, n = 30)
Number of subjects: 90
Study 27811457 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink group (Group P, n = 30)
Number of subjects: 90
Study 24365552 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic three-drug FDC formulation (3FDC)
Number of subjects: 20
Study 24365552 — intervention group
Group type: COMPARATOR
Intervention: 3FDC reference formulation
Number of subjects: 20
Study 23405793 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule plus apomorphine hydrochloride
Number of subjects: 226
Study 23405793 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine hydrochloride alone
Number of subjects: 226
Study 20461810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (2-24 mg/day)
Number of subjects: 0
Study 20461810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17716952 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational and life skills intervention
Number of subjects: 1560
Study 17716952 — intervention group
Group type: COMPARATOR
Intervention: General health education program
Number of subjects: 1560
Study 15949913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile monitoring system for foetal cardiotachometry
Number of subjects: 25
Study 12728300 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan infusion
Number of subjects: 20
Study 12728300 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 10569654 — intervention group
Group type: COMPARATOR
Intervention: Micronized fenofibrate
Number of subjects: 418
Study 9061426 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating fluid absorption during TURP
Number of subjects: 35
Study 9061426 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of crystalloid or colloid solution for intravenous fluid supplementation
Number of subjects: 35
Study 9061426 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cardiac disease
Number of subjects: 35
Study 9061426 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired kidney function and serum cortisol concentration
Number of subjects: 35
Study 1855356 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 32
Study 1855356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6360031 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 to 15 mg oral physostigmine daily
Number of subjects: 10
Study 6360031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31800477 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 48
Study 31800477 — intervention group
Group type: COMPARATOR
Intervention: CWI
Number of subjects: 48
Study 31800477 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 30503044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine
Number of subjects: 0
Study 30503044 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir plus tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 0
Study 29507944 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic target 130-140 mm Hg)
Number of subjects: 70
Study 29507944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic target <125 mm Hg)
Number of subjects: 70
Study 27343566 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-rectified signal averaging
Number of subjects: 279
Study 27343566 — intervention group
Group type: COMPARATOR
Intervention: Short-term variation
Number of subjects: 279
Study 27343566 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-rectified signal averaging and short-term variation
Number of subjects: 279
Study 25716389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises
Number of subjects: 50
Study 25716389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50